| |
| | GlycoGenesis adds scientist, operations head - Boston Business Journal: |
 | | Boston-based GlycoGenesis Inc. has filled two senior management positions as the company continues its evolution from an agricultural science company to a human drug company. |
 | | The company announced on Thursday the appointment of Jean Nichols, past president and chief technology officer of Hopkinton-based Seragen Inc., as its new interim chief scientific officer and Mark Staples, formerly senior director of pharmaceutical services at Waltham-based Praecis Pharmaceuticals Inc., as its vice president of operations and development. |
 | | GlycoGenesis, formerly known as SafeScience Inc., has a cancer drug, GCS-100, in Phase II human trials. |
| www.bizjournals.com /boston/stories/2002/09/16/daily43.html (402 words) |
|